Connect Biopharma (NASDAQ:CNTB) Stock Rating Reaffirmed as “Buy” by Canaccord Genuity Group

Connect Biopharma (NASDAQ:CNTB – Get Free Report)‘s stock had its “buy” rating reiterated by investment analysts at Canaccord Genuity Group in a research report issued to clients and investors on Tuesday, Benzinga reports.

Several other research analysts have also recently commented on the company. Oppenheimer reduced their target price on Connect Biopharma to $5.00 and set an “outperform” rating for the company in a research report on Tuesday, September 22nd. Weiss Ratings lowered shares of Connect Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, October 21st. HC Wainwright restated a “buy” rating on shares of Connect Biopharma in a research note on Wednesday, October 28th. BTIG Research reduced their price objective on shares of Connect Biopharma to $5.00 and set a “buy” rating for the company in a report on Wednesday, September 30th. Finally, Wall Street Zen lowered shares of Connect Biopharma from a “hold” rating to a “sell” rating in a research report on Saturday, October 31st. Eight investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $5.88.

Check Out Our Latest Research Report on CNTB

Connect Biopharma Stock Performance

Shares of NASDAQ:CNTB traded down $0.02 during trading on Tuesday, hitting $0.62. 367,687 shares of the stock were exchanged, compared to its average volume of 1,355,948. Connect Biopharma has a 1-year low of $0.55 and a 1-year high of $3.82. The company has a market capitalization of $39.36 million, a price-to-earnings ratio of -0.52 and a beta of 0.06. The company’s fifty day simple moving average is $1.02 and its 200-day simple moving average is $2.10. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.37 and a current ratio of 2.37.

Connect Biopharma (NASDAQ:CNTB – Get Free Report) last released its quarterly earnings data on Monday, November 16th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.01. The firm had revenue of $0.73 million for the quarter, compared to the consensus estimate of $0.12 million. Sell-side analysts expect that Connect Biopharma will post -1.09 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Bank of America Corp DE bought a new position in shares of Connect Biopharma during the first quarter valued at $41,000. Marshall Wace LLP boosted its stake in shares of Connect Biopharma by 12.0% in the 3rd quarter. Marshall Wace LLP now owns 376,029 shares of the company’s stock valued at $414,000 after purchasing an additional 40,387 shares in the last quarter. Knott David M Jr grew its holdings in shares of Connect Biopharma by 93.9% in the 1st quarter. Knott David M Jr now owns 387,835 shares of the company’s stock worth $1,016,000 after purchasing an additional 187,835 shares during the last quarter. ADAR1 Capital Management LLC bought a new stake in shares of Connect Biopharma in the 1st quarter worth about $1,945,000. Finally, BML Capital Management LLC lifted its holdings in Connect Biopharma by 574.1% during the 3rd quarter. BML Capital Management LLC now owns 3,864,400 shares of the company’s stock valued at $4,251,000 after purchasing an additional 3,291,113 shares during the last quarter. 58.72% of the stock is currently owned by institutional investors and hedge funds.

Connect Biopharma Company Profile

(Get Free Report)

Connect Biopharma is a biopharmaceutical company focused on developing treatments for inflammatory diseases, particularly conditions driven by T cells. The company has operated in the United States and China and has advanced its drug candidates through clinical development. Its lead candidate, rademikibart (formerly CBP-201), is an investigational antibody that targets the interleukin-4 receptor alpha pathway, which is involved in allergic inflammation. It has been studied for conditions including atopic dermatitis and asthma.

Further Reading

Analyst Recommendations for Connect Biopharma (NASDAQ:CNTB)

Receive News & Ratings for Connect Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Connect Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.